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Abstract  
Introduction: Progressing stroke (PS) and Crescendo Transient Ischemic Attacks 
(CTIA) are generally accepted, though unproven, indications for urgent 
anticoagulation and there remains evidence-free practice of intravenous heparin 
therapy in these patients.    
Methods and Materials: Consecutive PS and CTIA patients admitted in Mashhad  
Ghaem hospital during 2007- 2008, enrolled in a prospective observational study. PS 
and CTIA patients underwent intravenous heparin therapy 1000 units per hour for 3 
days without bolus dose. PS and CTIA patients who had a contraindication of 
intravenous heparin therapy received 80 mg Aspirin per day. Early clinical courses 
including improvement, stabilization, deterioration and development of residual 
stroke were evaluated in two therapeutic groups of PS and CTIA patients..  
Results: 170 PS patients (103 males, 67 females) with mean age 60.4±12.3 years and  
88  CTIA patients (50 males, 38 females) with mean age 60.1± 6.8 years were 
investigated. 141 PS and 64 CTIA patients received a short period of intravenous 
heparinization. The distribution of subtypes of early clinical course into two 
therapeutic groups of PS and CTIA patients was significantly different; X2=10.487, 
df=2 , p=0.005 and X2=6.72, df=2  , p=0.035 respectively. Distribution of residual 
stroke in two therapeutic groups of PS and CTIA patients was not significantly 
different; X2=1.443, df=1, p=0.23, OR=0.557 (0.212-1.462) and X2=1.01, df=1, 
p=0.315, OR=0.617 (0.24-1.587) respectively. 
Conclusion: PS and CTIA patients who received a short period of intravenous 
heparin therapy have significantly more probability of improvement and less 
probability of deterioration in their early clinical course.  
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Introduction 
Neurological deficits of ischemic 
stroke are frequently unstable during 
the early phase of stroke. Patients may 
show progressive deterioration with 
stepwise or nonstepwise fashions or 
fluctuations with periods of 
improvement1. Stroke in evolution is a 
non-specific term and is not 
synonymous with thrombosis in 
evolution.(1) Almost 30% of stroke 
patients’ condition worsened after 
being admitted in  the hospital1. 
Common practice considers that 
heparin followed by warfarin is 
indicated if observation provides clear 
evidence of recognizable worsening of 
an ischemic neurological disability.(2) 
This practice has been based on a set of  
incomplete and largely anectodal 
data.(2) In progressive stroke (PS), the 
focal ischemia worsens over several 
hours, or a day or two.(1,2) Progression 
of stroke in a stepwise fashion is easier 
to be regarded as stroke due to repeated 
episodes of thromboembolism than is 
an indolently PS.(3,4) Patients exhibiting 
stepwise progression may speculatively 
be considered as likely to benefit from 
anticoagulation.(3,4) Conversely, 
patients who are adding to their 
neurologic deficit in a nonstepwise 
progressing fashion are probably not 
exhibiting progressive thrombus 
formation and  will not be expected to 
respond to anticoagulation.(3,4) Brain 
edema accounts for most of the 
progression in the later situation2. 
Multiple or Crescendo Transient 
Ischemic Attacks (CTIA) are frequent 
in clinical practice. The term CTIA is 
defined as the occurance of multiple 
episodes over a few hours or days, 
often with increasing duration or 
severity.(5)  Some studies suggest that 
CTIA may represent a condition of 
impending brain infarction.(6) Common 
practice of medicine recommends short 
term anticoagulation in patients with 
CTIA without proven efficacy.(5,6) 
CTIA and major TIA require urgent 
evaluation and admission of the 
patient.(4) This observational study 
compares the clinical course of PS and 
CTIA patients who receive a short term 
intravenous heparin therapy with 
similar patients who take ultra low dose 
of Aspirin. 
 
Methods and Materials 
Consecutive patients with PS and 
CTIAs, admitted in Mashhad’s Ghaem 
hospital during 2007- 2008 enrolled in 
a prospective observational study. PS 
was defined as  the stepwise or 
fluctuated worsening of focal 
neurologic deficits over several hours, 
or a day or two1,2,7. These deficits could 
grow in severity, extent or number.(1,2,7)  
CTIA was defined as two TIAs within 
24 hours, three TIAs within 3 days or 4 
TIAs within 2 weeks.(1,6,7) These 
crescendo attacks  often increase in 
duration and severity of deficit.(1,5,6,7)  
Patients with CTIA were evaluated for 
presence of motor, sensory, aphasic 
and amarotic disturbances. Consecutive 
patients with PS and CTIA underwent 
intravenous heparin therapy 1000 units 
per hour for 3 days without an initial 
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bolus dose. PS Patients with coma, 
dense hemiplegia  or extensive signs of 
ischemia in the initial CT ( more than 
one-third of a hemisphere) were 
excluded.(8) PS and CTIA patients with 
a contraindication of anticoagulation 
therapy were excluded.(8) Antiplatelet 
drugs and warfarin were not 
administered during intravenous 
heparinization in this 3 days.(8) A brain 
CT was done for exclusion of 
intracranial hemorrhage before 
initiation of heparin therapy in all of 
these patients.(8,9) Prothrombin Time, 
Partial Thromboplastin Time and 
International Normalized Ratio were 
evaluated before anticoagulation 
therapy and thereafter once per day 
during heparin therapy.(9) PS and CTIA 
patients who had an initially abnormal 
coagulation test were excluded9. Short 
term intravenous heparin therapy in 
these patients is a routine therapeutic 
strategy in our instituation.(2,5) PS and 
CTIA patients with a contraindication 
of intravenous heparin therapy 
administered Aspirin 80 mg per day 
during hospitalization period.(2,5) The 
National Institute of Health Stroke 
Scale (NIHSS) was detected in all of 
the patients with PS and CTIA before 
heparinization and 3 days later.(10) The 
clinical course of these patients was 
categorized as improvement, 
stabilization and deterioration.(11) 
Improvement was defined as ≥3 points 
decrease and deterioration as ≥3 points 
increase in the second NIHSS.(10,11) 
Other patients were assumed as the 
stabilization group.(10,11) The same 
NIHSS assessment was performed for 
PS and CTIA patients who have taken 
Aspirin therapy.(10,11) Presence of 
stroke at 3 days after anticoagulation 
therapy was evaluated in all of our 
patients with PS and CTIA. All of 
these patients had a repeated CT after 
anticoagulation therapy for 
investigation of a visible infarct. A 
residual stroke was defined as the 
presence of ischemic focal neurological 
deficit lastingfor more than 24 hours or 
observation of a hypodense lesion in 
the CT corresponding to the 
manifestations.(11) The research was 
approved by ethics committee of 
Ghaem hospital. A signed informed 
consent form was filled by the patients 
or their first degree relatives. Pearson 
Chi-Square and Fisher  tests were 
performed for statistical anaslysis. 
 
Results 
170 patients (103 males, 67 females) 
with mean age 60.4±12.3 years 
developed PS. 141 PS patients (84 
males, 57 female) underwent a short 
term intravenous heparin therapy and 
29 PS patients(19 males, 10 females) 
received Aspirin 80 mg per day. 
Assessment of early stroke course in 
two therapeutic groups of PS patients is 
presented in Figure 1. 
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Figure 1:  Frequency rate of stroke course in two therapeutic groups of PS patients. 
Data are presented in percentage in each group separately. 
 
The frequency rate of subtypes of early 
stroke course was significantly 
different in our two therapeutic groups 
of PS patients; X2=10.487, df=2 , 
p=0.005. The influence of gender on 
early course of PS was not significant 
in the heparin and aspirin therapeutic 
groups; (X2=0.063, df=2, p=0.969) and 
(X2=0.021, df=2, p=0.990) 
respectively. 119 PS patients including 
68.1% of heparin and 79.3% of Aspirin 
groups developed a residual stroke. The 
distribution of residual stroke was not 
significantly different in our two 
therapeutic groups of PS patients; 
X2=1.443, df=  1, p=0.23, OR=0.557 
(0.212-1.462). The distribution of 
residual stroke based on the gender was 
not significantly different in PS 
patients who received short term 
intravenous heparinization; X2=0.089, 
df=1 , p=0.766, OR=1.11 (0.543-2.29). 
Difference in frequency of residual 
stroke based on the gender was not 
significant in PS patients  who 
underwent Aspirin therapy; X2=df=1, 
p=0.947, OR=0.938 (0.140-6.28). A 
residual stroke was developed in 30% 
of improvement, 100% of stabilization 
and 100% of deterioration courses 
among 170 PS patients. 88  patients (50 
males, 38 females) with mean age 
60.1± 6.8 years had CTIA. 64 patients 
(36 males, 28 females) with CTIA 
underwent short term intravenous 
heparinization and 24 CTIA patients 
(14 males, 10 females) received 
Aspirin 80 mg per day. Difference in 
the distribution of residual stroke in 
two therapeutic groups of CTIA 
patients was not significant; X2=1.01, 
df=1, p=0.315, OR=0.612 (0.24-1.587). 
The effect of gender on frequency of 
residual stroke in CTIA patients who 
received short term intravenous 
heparinization was not significant; 
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X2=0.367, df=1, p=0.545, OR, 0.734 
(0.27-1.997). Distribution of residual 
stroke was not significantly different 
based on the gender in CTIA patients 
who received aspirin therapy; X2=0.12, 
df=1 , p=0.729, OR=1.33 (0.261-
6.801). The frequency of early clinical 
course in two therapeutic groups of 
CTIA patients was significantly 
different; X2=6.72, df=2  , p=0.035. 
The distribution of early clinical course 
was not significantly different based on 
the gender in CTIA patients who 
received short period intravenous 
heparinization and aspirin therapy; 
(X2=0.12, df=2 , p=0.941) and 
(X2=0.171, df=2 , p=0.918) 
respectively. 
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Figure 2:  Frequency rate of early clinical  course  in two therapeutic groups of CTIA 
patients. Data are presented in percentage in each group separately. 
 
 
Figure 2 illustrates early clinical course 
of  88 CTIA patients in our two 
therapeutic groups . Motor, sensory, 
aphasic and amarotic nanifestations 
were found in 48%, 19%, 15% and 2% 
of our CTIA cases respectively.  Two 
PS and one CTIA  cases had minor 
hemorrhagic complications of 
intravenous anticoagulation including  
echymosis and hematuria. 
 
 
Discussion 
Controlled clinical trials performed 
more than 30 yeats ago suggested a 
beneficial effect of anticoagulation 
therapy in PS patients.(3,4) Based on the 
results of these trials, the indication for 
heparin therapy in this condition 
became widely accepted.(2,5) Other 
randomized and observational studies 
have not been conclusive in regard to 
the indication of anticoagulation in 
PS.(12) The data in aggregate suggested 
that heparin reduces the risk of 
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PS.(1,2,12) The lack of precise criteria for 
entry and outcome, non-blinded 
observation and small number of 
patients makes these studies inadequate 
by current methodological 
standards.(2,5,13) The main reason that 
72 hours was selected as cut off  point 
in assessment of our patients is that 
progression period in usually 
completed in 72 hours; on the other 
hand some of these patients are 
practically discharged in 3-4 days after 
anticoagulation therapy and the 
extention of hospitalization time just 
for research is not possible ethically. 
The use of heparin in PS patients has 
still been a matter of controversy in 
recent years.(14) Although short term 
intravenous heparinization 
demonstrated non significant influence 
on the development of residual stroke 
in our PS patients, it has confirmed a 
significant influence on early stroke 
course in PS patients. PS patients who 
have been on short period intravenous 
heparinization had significantly more 
probability for improvement and less 
probability for deterioration.  Heparin 
is widely used for lustering or 
CTIA.(2) This therapeutic strategy for 
CTIA has been largely due to the  
theoretical reasons and by extrapolation 
from the results of studies of 
anticoagulation for PS.(2,5) Although 
heparin appears to be the prefered 
treatment for CTIA, the data supporting 
its efficacy is meager and comes from 
old and limited studies.(15). However, 
intravenous heparinization has proved 
to be a safe therapy in these cases.(15) 
Despite the presence of reports of 
safety in administration of bolus of 
intravenous heparin while initiating 
heparin therapy,(16) bolus dose of 
heparin was not adminstered in our PS 
and CTIA patients and none of them 
developed major hemorrhagic 
complications.  The useof heparin in 
patients with CTIA(14) remains a 
relatively evidence-free practice. 
Although a short period intravenous 
heparnization was associated with a 
non significant effect on the 
development of residual stroke in our 
CTIA patients,  our CTIA patients who 
have been on this therapy had 
significantly more probability of 
improvement and less probability of 
deterioration in their early clinical 
course evaluation.  The common 
practice of neurologists in regard to 
using heparin in patients with PS and 
CTIA is different. United States 
neurologists are significantly more 
likely than Canadian neurologists to 
use intravenous heparin in PS and 
CTIA patients; (51% versus 33%) and 
(47% versus 9%) respectively.(17). The 
main reason of this difference is the 
effect of medicolegal factors on the 
neurologists.(17).  Up to date therapeutic 
guidelines of American and Europian 
stroke associations do not recommend 
short term intravenous anticoagulation 
in PS and CTIA patients.(18,19) This 
management is recommended in 
textbooks of cerebrovascular diseases 
and is the routine therapeutic strategy 
in our department.(2,5,8) It is not ethicaly 
possible to compare heparin with 
placebo in the PS and CTIA patients.  
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Thus we compared heparin therapy 
with ultra low dose of Aspirin.  
Although our clinical study suggests 
the use of  intravenous heparinization 
in PS and CTIA patients,  randomized 
and double blind clinical trials is 
recommended in this concept. 
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درﻣﺎن ﺑﻪ ﻫﭙﺎرﯾﻦ ورﯾﺪي ﺑﺮ ﺑﯿﻤﺎران ﺳﮑﺘﻪ ﻣﻐﺰي در ﺣﺎل  ﺗﺎﺛﯿﺮ
  ﻣﻐﺰي اﻓﺰاﯾﺶ ﯾﺎﺑﻨﺪهﭘﯿﺸﺮﻓﺖ و ﺣﻤﻼت ﮔﺬراي اﯾﺴﮑﻤﯽ
 
ﻧﮋاد، ﺳﯿﺎوش درﺧﺸﺎن، ﻋﻠﯽ ﻣﻠﺖ اردﮐﺎﻧﯽ، ﻗﺎﺳﻢ  ﻢ ﻧﯿﮑﺨﻮاه، اﻣﯿﺮرﺿﺎ ﺑﺮوﻣﻨﺪ، ﺳﯿﺪﺟﻮاد ﺣﺴﯿﻨﯽﮐﺎوﯾﺎن ﻗﻨﺪﻫﺎري، ﮐﺮﯾ
 ﻓﺘﺎح زاده
  
  446-736 ، 8831،زﻣﺴﺘﺎن82ﻓﺼﻠﻨﺎﻣﻪ ﻋﻠﻮم ﻣﻐﺰواﻋﺼﺎب اﯾﺮان، ﺳﺎل ﻫﺸﺘﻢ، ﺷﻤﺎره 
 
 هﭼﮑﯿﺪ
ﯾﺎﺑﻨـﺪه ﺑـﻪ ﻋﻨـﻮان  ﺳﮑﺘﻪ ﻣﻐﺰي درﺣﺎل ﭘﯿﺸﺮﻓﺖ و ﺣﻤﻼت ﮔﺬراي اﯾﺴﮑﻤﯽ اﻓـﺰاﯾﺶ  :ﺳﺎﺑﻘﻪ و ﻫﺪف 
در ﻃﺒﺎﺑﺖ روزﻣﺮه ﻧﯿﺰ درﻣـﺎن  .اﻧﺪﻫﺎي ﺛﺎﺑﺖ ﻧﺸﺪه درﻣﺎن ﺿﺪاﻧﻌﻘﺎدي ﻓﻮرﯾﺘﯽ ﭘﺬﯾﺮﻓﺘﻪ ﺷﺪه  اﻧﺪﯾﮑﺎﺳﯿﻮن
  . آن اداﻣﻪ داردﺑﺎ ﻫﭙﺎرﯾﻦ ورﯾﺪي در اﯾﻦ ﺑﯿﻤﺎران ﺑﺪون اﺛﺒﺎت ﻗﻄﻌﯽ ﻓﺎﯾﺪه
ﺶ ﺑﯿﻤﺎران ﭘﯽ در ﭘﯽ ﺑﺎ ﺳﮑﺘﻪ ﻣﻐﺰي ﭘﯿﺸﺮوﻧﺪه و ﺣﻤﻼت ﮔﺬراي اﯾﺴﮑﻤﯽ ﻣﻐﺰي اﻓﺰاﯾ  :روش ﺑﺮرﺳﯽ 
 اﻧـﺪ در ﯾـﮏ ﻣﻄﺎﻟﻌـﻪ  ﺑـﺴﺘﺮي ﺷـﺪه 7002 -8002ﮐﻪ در ﺑﯿﻤﺎرﺳﺘﺎن ﻗﺎﺋﻢ ﻣـﺸﻬﺪ در ﺳـﺎﻟﻬﺎي  ﯾﺎﺑﻨﺪه
ﻫﭙﺎرﯾﻦ ورﯾـﺪي   واﺣﺪ در ﺳﺎﻋﺖ0001ﺑﯿﻤﺎران ﻓﻮق ﺗﺤﺖ درﻣﺎن ﺑﺎ . ﻧﮕﺮ ﻗﺮار ﮔﺮﻓﺘﻨﺪ اي آﯾﻨﺪه  ﻣﺸﺎﻫﺪه
رﯾﺪي ﺑـﺎ ﮐﻮﻧﺘﺮااﻧﺪﯾﮑﺎﺳﯿﻮن درﻣﺎن و  ﺑﯿﻤﺎراﻧﯽ ﮐﻪ . ﺑﺪون دوز اوﻟﯿﻪ ﺑﻪ ﻣﺪت ﺣﺪاﻗﻞ ﺳﻪ روز ﻗﺮار ﮔﺮﻓﺘﻨﺪ 
ﺳﯿﺮ ﺑﺎﻟﯿﻨﯽ زودرس ﭘﺲ از ﺳـﻪ روز . درﯾﺎﻓﺖ ﮐﺮدﻧﺪ  ﻣﯿﻠﯿﮕﺮم آﺳﭙﺮﯾﻦ روزاﻧﻪ 08ﻫﭙﺎرﯾﻦ را داﺷﺘﻨﺪ ﻧﯿﺰ 
در دو ﮔـﺮوه درﻣـﺎﻧﯽ از ﺑﯿﻤـﺎران  ﺗﺜﺒﯿﺖ و وﺧﺎﻣﺖ و اﯾﺠﺎد ﺳﮑﺘﻪ ﻣﻐﺰي ﺑﺮﺟﺎي ﻣﺎﻧـﺪه   ﺷﺎﻣﻞ ﺑﻬﺒﻮدي 
  .ﻓﻮق ﺑﺮرﺳﯽ ﺷﺪ
  ±21/3ﭘﯿﺸﺮﻓﺖ و ﻣﯿـﺎﻧﮕﯿﻦ ﺳـﻨﯽ ﺑﺎ ﺳﮑﺘﻪ ﻣﻐﺰي در ﺣﺎل (  زن76 ﻣﺮد و 301) ﺑﯿﻤﺎر 071 :ﻫﺎ ﯾﺎﻓﺘﻪ
ﺣﻤـﻼت ﮔـﺬراي اﯾـﺴﮑﻤﯽ ﻣﻐـﺰي اﻓـﺰاﯾﺶ ﯾﺎﺑﻨـﺪه و  ﺑـﺎ (  زن 83 ﻣﺮد و 05)  ﺑﯿﻤﺎر 88 ﺳﺎل و 06/4
 46 ﺑﯿﻤﺎر ﺑﺎ ﺳـﮑﺘﻪ ﻣﻐـﺰي در ﺣـﺎل ﭘﯿـﺸﺮﻓﺖ و 141. ﺑﺮرﺳﯽ ﺷﺪﻧﺪ  ﺳﺎل 06/1 ± 6/8ﻣﯿﺎﻧﮕﯿﻦ ﺳﻨﯽ 
ﻫﭙﺎرﯾﻦ ورﯾﺪي را درﯾﺎﻓﺖ اﯾﺴﮑﻤﯽ ﻣﻐﺰي اﻓﺰاﯾﺶ ﯾﺎﺑﻨﺪه درﻣﺎن ﮐﻮﺗﺎه ﻣﺪت ﺑﺎ  ﺑﯿﻤﺎر ﺑﺎ ﺣﻤﻼت ﮔﺬراي 
در  ﺗﻮزﯾﻊ ﻓﺮاواﻧﯽ اﻧﻮاع ﺳﯿﺮ ﺑﺎﻟﯿﻨﯽ زودرس ﺑﯿﻦ دو ﮔﺮوه درﻣﺎﻧﯽ از ﺑﯿﻤـﺎران ﺑـﺎ ﺳـﮑﺘﻪ ﻣﻐـﺰي  .ﻧﻤﻮدﻧﺪ
 ﺑﺘﺮﺗﯿـﺐ  دار داﺷـﺖ ﺣﺎل ﭘﯿﺸﺮﻓﺖ و ﺣﻤﻼت ﮔﺬراي اﯾـﺴﮑﻤﯽ ﻣﻐـﺰي اﻓـﺰاﯾﺶ ﯾﺎﺑﻨـﺪه ﺗﻔـﺎوت ﻣﻌﻨـﯽ 
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ﻣﻐﺰي در ﺣﺎل ﭘﯿﺸﺮﻓﺖ و ﺣﻤﻼت ﮔـﺬراي اﯾـﺴﮑﻤﯽ ﻣﻐـﺰي اﻓـﺰاﯾﺶ ﺳﮑﺘﻪ  ﺑﯿﻤﺎران ﺑﺎ  : ﮔﯿﺮي ﻧﺘﯿﺠﻪ
ﻫﭙﺎرﯾﻦ ورﯾﺪي ﻫﺴﺘﻨﺪ اﺣﺘﻤﺎل ﺑﯿﺸﺘﺮي از ﺑﻬﺒﻮد و اﺣﺘﻤﺎل ﮐﻤﺘﺮي از ﺑـﺪﺗﺮ  ﯾﺎﺑﻨﺪه ﮐﻪ ﺗﺤﺖ درﻣﺎن ﺑﺎ 
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